Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Video

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

This is a new option that oncologists should consider for frail patients who have soft tissue sarcoma.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS
Related Content
Kristen K. Buck, MD, executive vice president, Research and Development, chief medical officer, Lisata Therapeutics

FDA Grants Orphan Drug Designation to LSTA1 in Osteosarcoma

April 10th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
Kristen K. Buck, MD, executive vice president, Research & Development, chief medical officer, Lisata

FDA Grants Rare Pediatric Disease Designation to LSTA1 in Osteosarcoma

March 29th 2024
Article
Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

December 29th 2022
Podcast
FDA

FDA Approves 2 Denosumab Biosimilars for All Reference Medicine Indications

March 5th 2024
Article
Bernd Kasper, MD, PhD, chair, Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg

EMA Validates Marketing Authorization Application for Nirogacestat in Desmoid Tumors

February 29th 2024
Article